Trading Update

 1 June 2015

Cyprotex PLC

("Cyprotex" or the "Company" or the "Group")

Trading update

Cyprotex PLC (AIM: CRX), the preclinical ADME-Tox services company, provides an update on profit guidance for the year to 31 December 2015

Trading update

The financial performance of the Company for the first 5 months of the year is ahead of expectations driven by strong growth in UK revenues and whilst there remain challenges, particularly in the US operations, the Board expects that its full year revenues and profits will exceed current market expectations.

For further information:

Notes to Editors:

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites in Macclesfield, near Manchester in the UK, Watertown, MA and Kalamazoo MI in the US. The Company was established in 1999 and works with more than 1,100 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com